{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:53:17Z","timestamp":1781628797120,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic decompensation is life-threatening in children with organic acidemia (OA). This study aims to evaluate the efficacy of continuous renal replacement therapy (CRRT) in treating patients with OA complicated by decompensated metabolic acidosis in pediatric intensive care units (PICU) and to explore its impact on organ function impairment associated with this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data of children with OA developed decompensated metabolic acidosis admitted to PICU between 2013 and 2024 were collected and retrospectively analyzed. The patients were divided into two groups: the CRRT treatment group (admitted after 2019) and the conventional treatment group (admitted before 2019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-six patients were included in the study. After 24\u2009hours of CRRT therapy, there was a significant decrease in levels of lactic acid, plasma ammonia, blood urea nitrogen, creatinine, troponin, myoglobin and neuron-specific enolase (NSE) compared to the conventional treatment group. After 48\u2009hours of CRRT therapy, alanine aminotransferase and aspartate aminotransferase levels decreased in comparison with the conventional treatment group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). After 5\u2009days of therapy, a significant decline in NSE persisted in the CRRT group compared to the conventional treatment group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In the conventional group, organ injury biomarkers increased at 24\u2009hours and gradually declined over time, whereas no elevation of these biomarkers was observed in the CRRT group. The duration of mechanical ventilation and the length of stay in the PICU were significantly shorter in the CRRT group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patient with OA complicated by decompensated metabolic acidosis, the treatment combined with CRRT can efficiently remove metabolites, thereby avoid neuron and the major organs from further injury. Application of CRRT can help these patients recover earlier from the metabolic crisis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04169-2","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:55:08Z","timestamp":1767041708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and organ protective effects of continuous renal replacement therapy in children with organic acidemia complicated by decompensated acidosis: a retrospective study in PICU"],"prefix":"10.1186","volume":"20","author":[{"given":"Lili","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3632-4224","authenticated-orcid":false,"given":"Yueniu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianshu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiLi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"4169_CR1","doi-asserted-by":"publisher","unstructured":"Forny P, H\u00f6rster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44(3):566\u201392. https:\/\/doi.org\/10.1002\/jimd.12370","DOI":"10.1002\/jimd.12370"},{"key":"4169_CR2","doi-asserted-by":"publisher","unstructured":"Lee N, Kim D. Toxic metabolites and inborn errors of amino acid metabolism: what one informs about the other. Metabolites. 2022;12(6):527. https:\/\/doi.org\/10.3390\/metabo12060527","DOI":"10.3390\/metabo12060527"},{"key":"4169_CR3","doi-asserted-by":"publisher","unstructured":"Ning B, Ye S, Lyu Y, et al. Effect of high-volume hemofiltration on children with sepsis. Transl Pediatr. https:\/\/doi.org\/10.21037\/tp.2020.03.13.","DOI":"10.21037\/tp.2020.03.13"},{"key":"4169_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040718","author":"WY Chen","year":"2021","unstructured":"Chen WY, Cai LH, Zhang ZH, et al. The timing of continuous renal replacement therapy initiation in sepsis-associated acute kidney injury in the intensive care unit: the CRTSAKI study (Continuous RRT Timing in Sepsis-associated AKI in ICU): study protocol for a multicentre, randomised controlled trial. BMJ Open. 2021;11(2):e040718. https:\/\/doi.org\/10.1136\/bmjopen-2020-040718","journal-title":"BMJ Open"},{"key":"4169_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0267-8","author":"R Raina","year":"2020","unstructured":"Raina R, Bedoyan JK, Lichter-Konecki U, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020. https:\/\/doi.org\/10.1038\/s41581-020-0267-8.","journal-title":"Nat Rev Nephrol"},{"key":"4169_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/children6040053","author":"F Aygun","year":"2019","unstructured":"Aygun F, Varol F, Aktuglu-Zeybek C, et al. Continuous renal replacement therapy with high flow rate can effectively, safely, and quickly reduce plasma ammonia and leucine levels in children. Children (basel). 2019. https:\/\/doi.org\/10.3390\/children6040053.","journal-title":"Children (basel)"},{"key":"4169_CR7","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1811-8","author":"H Akduman","year":"2020","unstructured":"Akduman H, Okulu E, Emino\u011flu FT, et al. Continuous venovenous hemodiafiltration in the treatment of newborns with an inborn metabolic disease: a single center experience. Turk J Med Sci. 2020. https:\/\/doi.org\/10.3906\/sag-1811-8.","journal-title":"Turk J Med Sci"},{"key":"4169_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.07.013","author":"HP Cudr\u00e9-Cung","year":"2016","unstructured":"Cudr\u00e9-Cung HP, Zavadakova P, Vale-Pereira S, et al. Ammonium accumulation is a primary effect of 2-methylcitrate exposure in an in vitro model for brain damage in methylmalonic aciduria. Mol Genet Metab. 2016. https:\/\/doi.org\/10.1016\/j.ymgme.2016.07.013.","journal-title":"Mol Genet Metab"},{"key":"4169_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0556-2","author":"P Garcia","year":"2008","unstructured":"Garcia P, Martins E, Diogo L, et al. Outcome of three cases of untreated maternal glutaric aciduria type I. Eur J Pediatr. 2008. https:\/\/doi.org\/10.1007\/s00431-007-0556-2. Epub 2007 Jul 28.","journal-title":"Eur J Pediatr"},{"key":"4169_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-024-00646-0","author":"S Ling","year":"2024","unstructured":"Ling S, Wu S, Shuai R, et al. Clinical outcomes of patients with mut-type methylmalonic acidemia identified through expanded newborn screening in China. Hum Genomics. 2024. https:\/\/doi.org\/10.1186\/s40246-024-00646-0.","journal-title":"Hum Genomics"},{"key":"4169_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.07.009","author":"BL Therrell Jr","year":"2014","unstructured":"Therrell BL Jr, Lloyd-Puryear MA, Camp KM, Mann MY. Inborn errors of metabolism identified via newborn screening: Ten-year incidence data and costs of nutritional interventions for research agenda planning. Mol Genet Metab. 2014. https:\/\/doi.org\/10.1016\/j.ymgme.2014.07.009.","journal-title":"Mol Genet Metab"},{"key":"4169_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0130-8","author":"MR Baumgartner","year":"2014","unstructured":"Baumgartner MR, H\u00f6rster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014. https:\/\/doi.org\/10.1186\/s13023-014-0130-8.","journal-title":"Orphanet J Rare Dis"},{"key":"4169_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12566","author":"N Boy","year":"2023","unstructured":"Boy N, M\u00fchlhausen C, Maier EM, et al. Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: third revision. J Inherit Metab Dis. 2023. https:\/\/doi.org\/10.1002\/jimd.12566.","journal-title":"J Inherit Metab Dis"},{"key":"4169_CR14","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2018.01026","author":"X Zhou","year":"2018","unstructured":"Zhou X, Cui Y, Han J. Methylmalonic acidemia: current status and research priorities. Intractable Rare Dis Res. 2018. https:\/\/doi.org\/10.5582\/irdr.2018.01026.","journal-title":"Intractable Rare Dis Res"},{"key":"4169_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-014-9687-6","author":"S Fischer","year":"2014","unstructured":"Fischer S, Huemer M, Baumgartner M, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis. 2014. https:\/\/doi.org\/10.1007\/s10545-014-9687-6.","journal-title":"J Inherit Metab Dis"},{"key":"4169_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.09.026","author":"KA Chapman","year":"2012","unstructured":"Chapman KA, Gropman A, MacLeod E, et al. Acute management of propionic acidemia. Mol Genet Metab. 2012. https:\/\/doi.org\/10.1016\/j.ymgme.2011.09.026.","journal-title":"Mol Genet Metab"},{"key":"4169_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25233","author":"N Boy","year":"2018","unstructured":"Boy N, Mengler K, Thimm E, et al. Newborn screening: a disease-changing intervention for glutaric aciduria type 1. Ann Neurol. 2018. https:\/\/doi.org\/10.1002\/ana.25233.","journal-title":"Ann Neurol"},{"key":"4169_CR18","doi-asserted-by":"publisher","DOI":"10.4103\/ijn.IJN_309_17","author":"KTC Goutham","year":"2019","unstructured":"Goutham KTC, Harichandrakumar KT, Dhanin P, et al. Persistent metabolic acidosis on regular hemodialysis or peritoneal dialysis. Indian J Nephrol. 2019. https:\/\/doi.org\/10.4103\/ijn.IJN_309_17.","journal-title":"Indian J Nephrol"},{"key":"4169_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-003-1389-5","author":"DK Rajpoot","year":"2004","unstructured":"Rajpoot DK, Gargus JJ. Acute hemodialysis for hyperammonemia in small neonates. Pediatr Nephrol. 2004. https:\/\/doi.org\/10.1007\/s00467-003-1389-5.","journal-title":"Pediatr Nephrol"},{"key":"4169_CR20","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.167044","author":"KM Gulla","year":"2015","unstructured":"Gulla KM, Sachdev A, Gupta D, et al. Continuous renal replacement therapy in children with severe sepsis and multiorgan dysfunction - a pilot study on timing of initiation. Indian J Crit Care Med. 2015. https:\/\/doi.org\/10.4103\/0972-5229.167044.","journal-title":"Indian J Crit Care Med"},{"key":"4169_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518776426","author":"Y Wang","year":"2018","unstructured":"Wang Y, Lu J, Tao Y. Impact of daytime continuous veno-venous haemofiltration on treatment of paediatric tumour lysis syndrome. J Int Med Res. 2018. https:\/\/doi.org\/10.1177\/0300060518776426.","journal-title":"J Int Med Res"},{"key":"4169_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000896","author":"Y Cui","year":"2016","unstructured":"Cui Y, Zhang YC, Kang YL, et al. High-volume hemofiltration in critically ill patients with secondary hemophagocytic Lymphohistiocytosis\/Macrophage activation syndrome: a prospective study in the PICU. Pediatr Crit Care Med. 2016. https:\/\/doi.org\/10.1097\/PCC.0000000000000896.","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"4169_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1051\/ject\/201749064","volume":"49","author":"JW Gander","year":"2017","unstructured":"Gander JW, Rhone ET, Wilson WG, et al. Veno-venous extracorporeal membrane oxygenation for continuous renal replacement in a neonate with propionic acidemia. J Extra Corpor Technol. 2017, Mar;49(1):64\u201366.","journal-title":"J Extra Corpor Technol"},{"key":"4169_CR24","doi-asserted-by":"publisher","DOI":"10.1159\/000328961","author":"M Thomas","year":"2011","unstructured":"Thomas M, Moriyama K, Ledebo I. AN69: evolution of the world\u2019s first high permeability membrane. Contrib Nephrol. 2011. https:\/\/doi.org\/10.1159\/000328961.","journal-title":"Contrib Nephrol"},{"key":"4169_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1428089","author":"KK Wang","year":"2018","unstructured":"Wang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018. https:\/\/doi.org\/10.1080\/14737159.2018.1428089.","journal-title":"Expert Rev Mol Diagn"},{"key":"4169_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25095040","author":"AS Babkina","year":"2024","unstructured":"Babkina AS, Lyubomudrov MA, Golubev MA, et al. Neuron-specific enolase-What are we measuring? Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25095040.","journal-title":"Int J Mol Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04169-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04169-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04169-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:56:33Z","timestamp":1781625393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04169-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04169-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients with decompensated metabolic acidosis due to OA admitted to PICU were recommended to receive CRRT therapy since 2019 in the present hospital. All patients undergoing CRRT provided informed consent for central venous catheterization and blood purification treatment. This retrospective observation study received approval from the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The requirement for written informed consent for the study was waived by the committee, as all data were used retrospectively and de-identified (Approval No. XHEC-D-2024\u2013197).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The requirement for written informed consent for the study was waived, as all data were used retrospectively and de-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"636"}}